Literature DB >> 6086443

Diabetes mellitus in chronic active hepatitis and cirrhosis.

M E Kingston, M A Ali, M Atiyeh, R J Donnelly.   

Abstract

One hundred consecutive patients with nonautoimmune chronic active hepatitis (51% HBsAg-positive), 50 patients with cirrhosis (38% HBsAg-positive), 25 patients with chronic persistent hepatitis, and 118 patients with hepatoma who were seen at this hospital were reviewed to determine the prevalence and characteristics of glucose intolerance and diabetes in these conditions. Diabetes (fasting serum glucose greater than 7.8 mmol/L, 140 mg/dl on two separate occasions) was present in 8% of patients with chronic persistent hepatitis and mild chronic active hepatitis, 44% of patients with severe chronic active hepatitis, 40% of patients with cirrhosis, and 15% of patients with hepatoma, compared with 7% of all other patients aged 35 yr or over, undergoing liver biopsy. Compared with this high prevalence of diabetes in liver disease, only 3% of diabetic patients referred to the hospital diabetic clinic had chronic hepatitis or cirrhosis. Glucose tolerance was similar in chronic active hepatitis and cirrhosis and was characterized initially by basal hyperinsulinemia, normal basal glucose levels but elevated serum glucose following glucose loading, and evidence of insulin resistance. We suggest that the high prevalence of diabetes in chronic active hepatitis and cirrhosis in Saudi Arabia is due to the insulin resistance of chronic liver disease acting over many years in a population with a high genetic predisposition to diabetes.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6086443

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  16 in total

1.  Viruses and diabetes: is there something sweet about hepatitis C infection?

Authors:  A L Mason; G J Alexander
Journal:  Ochsner J       Date:  2001-07

2.  Diabetes mellitus associated with chronic liver disease.

Authors:  S Gentile; R Marmo; M Coltorti; C Del Vecchio Blanco
Journal:  Dig Dis Sci       Date:  1987-08       Impact factor: 3.199

3.  Liver cirrhosis as a diabetogenic condition.

Authors:  L Cacciatore; G Cozzolino; M G Giardina; F De Marco; G Francica; A Lonardo; M Matarazzo; A Varriale
Journal:  Dig Dis Sci       Date:  1986-01       Impact factor: 3.199

4.  Diabetes mellitus impairs the response to intra-arterial chemotherapy in hepatocellular carcinoma.

Authors:  Yin-Hsun Feng; Cheng-Yao Lin; Wen-Tsung Huang; Chia-Ling Wu; Jui-Lung Fang; Chao-Jung Tsao
Journal:  Med Oncol       Date:  2010-08-24       Impact factor: 3.064

5.  Safe and effective treatment of diabetes mellitus associated with chronic liver diseases with an alpha-glucosidase inhibitor, acarbose.

Authors:  Y Kihara; Y Ogami; A Tabaru; H Unoki; M Otsuki
Journal:  J Gastroenterol       Date:  1997-12       Impact factor: 7.527

6.  Concurrent hyperglycemia does not influence the long-term prognosis of unresectable hepatocellular carcinomas.

Authors:  Xiao-Ping Li; Zhen Chen; Zhi-Qiang Meng; Wen-Xia Huang; Lu-Ming Liu
Journal:  World J Gastroenterol       Date:  2003-08       Impact factor: 5.742

7.  Glucose intolerance in Chinese patients with chronic hepatitis C.

Authors:  Liang-Kung Chen; Shinn-Jang Hwang; Shih-Tzer Tsai; Jiing-Chyuan Luo; Shou-Dong Lee; Full-Young Chang
Journal:  World J Gastroenterol       Date:  2003-03       Impact factor: 5.742

8.  Chronic Liver Disease-Associated Hospitalizations Among Adults with Diabetes, National Inpatient Sample, 2001-2012.

Authors:  Kathy K Byrd; Jason M Mehal; Sarah F Schillie; Robert C Holman; Dana Haberling; Trudy Murphy
Journal:  Public Health Rep       Date:  2015 Nov-Dec       Impact factor: 2.792

Review 9.  [Gastrointestinal complications of diabetes mellitus].

Authors:  M Vogt; H E Adamek; J C Arnold; D Schilling; T Schleiffer; J F Riemann
Journal:  Med Klin (Munich)       Date:  1999-06-15

10.  Prevalence and determinants of diabetes mellitus among Iranian patients with chronic liver disease.

Authors:  Seyed M Alavian; Behzad Hajarizadeh; Fariborz Nematizadeh; Bagher Larijani
Journal:  BMC Endocr Disord       Date:  2004-11-19       Impact factor: 2.763

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.